Antoine Yver - Articles and news items


AstraZeneca welcomes positive data on the combination of olaparib and cediranib for the treatment of ovarian cancer patients

Industry news / 2 June 2014 / AstraZeneca

As part of the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), Dr Joyce Liu presented data on a Phase II study conducted by the American National Cancer Institute…


AstraZeneca initiates phase III clinical programme for selumetinib, a treatment in development for patients with non-small-cell lung cancer

Industry news / 22 October 2013 / AstraZeneca

SELECT-1 will be the first Phase III study to investigate whether a MEK inhibitor in combination with chemotherapy is superior to chemotherapy alone…


AstraZeneca initiates Phase III clinical programme for olaparib, a treatment in development for patients with BRCA mutated ovarian cancer

Industry news, News / 4 September 2013 / AstraZeneca

As a result of the initiation of this programme, a pre-tax impairment charge of $285 million will be reversed and the asset restored to our balance sheet in the third quarter of 2013…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...